X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the acquisition, Novartis will strengthen its oncology pipeline with CPI-0610 (pelabresib), a novel and potentially practice changing treatment option with a well-tolerated safety profile provided in combination with ruxolitinib for patients with myelofibrosis (MF).
Lead Product(s): Pelabresib,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: CPI-0610
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $2,897.9 million Upfront Cash: $2,897.9 million
Deal Type: Acquisition February 05, 2024
Details:
CPI-0610 (pelabresib monohydrate) is an investigational BET inhibitor. It is being developed in combination with the JAK inhibitor ruxolitinib for the treatment of myelofibrosis.
Lead Product(s): Pelabresib,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: CPI-0610
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 20, 2023
Details:
Pelabresib (CPI-0610) is an investigational selective small molecule designed to promote anti-tumor activity by inhibiting the function of bromodomain and extra-terminal domain proteins to decrease the expression of abnormally expressed genes in cancer.
Lead Product(s): Pelabresib,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: CPI-0610
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2022
Details:
Pelabresib durably reduced inflammatory cytokines such as tumor necrosis factor alpha (TNF alpha) and interleukin 18 (IL18) as early as 2 weeks and maintained through 24 weeks of treatment, based on an analysis of patient samples.
Lead Product(s): Pelabresib,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: CPI-0610
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2021
Details:
Constellation's lead product candidates, pelabresib (CPI-0610), a BET inhibitor, and CPI-0209, a 2nd-gen EZH2 inhibitor, are in mid- to late-stage clinical trials and have broad therapeutic potential to offer benefits to patients with various hematological and solid tumors.
Lead Product(s): Pelabresib,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: CPI-0610
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: MorphoSys
Deal Size: $1,700.0 million Upfront Cash: $1,700.0 million
Deal Type: Acquisition June 02, 2021
Details:
Event includes a review of the clinical and translational data from MANIFEST presented during ASH, including 24-week data from 50-60 first line and 90-100 second line myelofibrosis patients. MANIFEST is an open-label Phase 2 trial of CPI-0610 in patients with myelofibrosis.
Lead Product(s): Pelabresib
Therapeutic Area: Oncology Product Name: CPI-0610
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
37 of 51 evaluable patients (73%) achieved a 35% reduction in spleen volume (SVR35) at 12 weeks and had a median spleen volume reduction of 51% after receiving Arm 3 (1L) – CPI-0610 + ruxolitinib.
Lead Product(s): Pelabresib,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Evidence of clinical activity was seen both as monotherapy and in combination with ruxolitinib. If these preliminary data are confirmed in further testing, CPI-0610 could become part of a new standard of care in myelofibrosis.
Lead Product(s): Pelabresib,Ruxolitinib Phosphate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
